The randomized phase 2 ImmunoPRISM trial found that teclistamab produced more complete clinical responses than lenalidomide-dexamethasone in patients with high-risk smoldering multiple myeloma, though longer follow-up is needed to confirm durable prevention of progression to act…
Teclistamab Shows Higher Response Rates Than Standard Therapy in High-Risk Smoldering Myeloma
The randomized phase 2 ImmunoPRISM trial found that teclistamab produced more complete clinical responses than lenalidomide-dexamethasone in patients with high-risk smoldering multiple myeloma, though longer follow-up is needed to confirm durable prevention of progression to active disease.
Lenalidomide · Wikimedia — licence per file · rights
This item was produced with AI assistance under the editorial responsibility of Haydamax OÜ.
Monitoring item. The full text is not distributed. Extract and source below.